Description: HLB Pharmaceutical Co., Ltd, a pharmaceutical company, develops peptide drugs in South Korea. The company offers skeletal muscle relaxants, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease. It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services. The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020. HLB Pharmaceutical Co., Ltd was founded in 1998 and is headquartered in Namyangju, South Korea.
Home Page: www.c-tri.co.kr
778-1 Ilpaedong
Namyangju-Si,
South Korea
Phone:
82 411 1500
Officers
| Name | Title |
|---|---|
| Mr. Wan-Joo Kim | Chief Exec. Officer and Representative Director |
| Mr. Jong-Bin Kim | Sr. Managing Director |
| Dr. Jung-Bok Yoo | Managing Director |
| Dr. Dong-Yeop Lee | Managing Director |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 5.6005 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |